

Mesenchymal stromal cell therapy for Degenerative Disc Disease

Patient progression report | January 2022 – June 2022

Benchmark™
Powered by inCytes™



Clinical Care Program

During the first half of the year 2022, 76 patients* were treated for this pathology at thoracolumbar level.

Figure 1. Shows the age and sex of the treated patients.

32 patients started follow-up, of whom 29 (91%) answered the questionnaires at 3 months, 30 (94%) answered at 6 months and 22 (69%) at 12 months post-therapy.

Pain assessment

The Visual Analogue Scale (VAS) measures the amount of pain experienced. Scores range from 0 no pain to 10 extreme pain.

Figure 2. Improvement at 6 months post-therapy with an average reduction of 2.3 points (↓37%), which is maintained up to 12 months post-therapy.

Disability assessment




The Oswestry Disability Index (ODI) assesses how pain can affect activities of daily living.

Final scores range from 0% to 100% and are interpreted according to the following table:

Figure 3. Improvement at 6 months post-therapy with an average reduction of 9.8 points (↓29%), which is maintained until 12 months post-therapy.

We plan to continue monitoring patients and will issue updates when additional data becomes available.

Score	Disability
0-20	Minimum
21-40	Moderate
41-60	Severe
61-80	Disabled
81-100	Bedridden



*Patients gave their consent to follow them through the InCytes web platform and publish their clinical data.

Report prepared by: Luz Adriana Palacio, BioXcellerator scientific and research team.